Site icon fundsforNGOs

3rd Call for Proposals on Metabolic Health and Longevity Grant Program

Open Call for Proposals for Farm Safety, Health and Wellbeing Projects (Ireland)

Deadline: 30-Jan-2026

The AXA Research Fund, in partnership with Swiss Re, invites proposals under the 3rd Call for the Joint Risk Resilience Partnership focused on personalized metabolic interventions. Research should leverage genomics, metabolomics, behavioral science, and digital health tools to optimize health outcomes, assess cost-effectiveness, and inform tiered interventions. Grants of up to €150,000 are available for 9–18 month projects, with applications due by 30 January 2026.

Overview of the Call

The AXA-Swiss Re Joint Risk Resilience Partnership seeks research projects addressing personalized interventions for metabolic health, including obesity, diabetes, and related early-onset health risks. The program encourages integrative approaches combining genomics, metabolomics, behavioral science, and digital health solutions.

Why It Matters

Rising trends in obesity, diabetes, and early-onset cancers highlight the urgent need for personalized metabolic interventions. Effective strategies can:

Research Focus Areas

Projects may explore:

Key Research Objectives

Triple-Win Framework

The expected outcomes include benefits for:

Project Duration and Funding

Eligible Applicants

Application and Submission Process

Required Deliverables and Reporting

Tips for Applicants

FAQ

1. Who can apply?
Academic institutions worldwide, either individually or as part of a consortium, led by a Principal Investigator.

2. What is the maximum grant amount?
Up to €150,000 per project.

3. What is the project duration?
9 to 18 months, starting between October 2026 and January 2027.

4. What research areas are prioritized?
Genomics, metabolomics, behavioral science, cost-effectiveness analysis, and digital health applications for metabolic interventions.

5. How should applications be submitted?
Through the European Science Foundation platform in English.

6. What are the reporting requirements?
Mid-term and final reports, plus dissemination via publications and presentations.

7. Can projects include pharmacologic interventions?
Yes, including GLP-1 drugs, bariatric surgery, and related interventions, assessed for effectiveness and cost-efficiency.

Conclusion

The AXA-Swiss Re Joint Risk Resilience Partnership 3rd Call provides an opportunity to advance personalized metabolic interventions through integrative research combining multiomics, behavioral science, and digital health tools. Selected projects will contribute to improved individual outcomes, scalable healthcare solutions, and optimized insurance models, addressing pressing global metabolic health challenges.

For more information, visit AXA Research Fund.

Exit mobile version